Assembly Biosciences (NASDAQ:ASMB) had its price objective lowered by B. Riley to $45.00 in a research report report published on Tuesday morning. B. Riley currently has a neutral rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Assembly Biosciences’ Q2 2018 earnings at ($0.95) EPS, Q3 2018 earnings at ($0.95) EPS, Q4 2018 earnings at ($0.95) EPS, FY2018 earnings at ($3.65) EPS, Q1 2019 earnings at ($0.29) EPS, Q2 2019 earnings at ($0.29) EPS, Q3 2019 earnings at ($0.29) EPS, Q4 2019 earnings at ($0.29) EPS, FY2019 earnings at ($1.15) EPS, FY2020 earnings at ($2.21) EPS, FY2021 earnings at ($2.77) EPS and FY2022 earnings at ($5.21) EPS.
Several other analysts have also recently issued reports on ASMB. Zacks Investment Research cut Assembly Biosciences from a buy rating to a hold rating in a research report on Monday, January 15th. BidaskClub raised Assembly Biosciences from a hold rating to a buy rating in a research report on Tuesday, January 30th. ValuEngine raised Assembly Biosciences from a sell rating to a hold rating in a research report on Saturday, February 3rd. Jefferies Group increased their target price on Assembly Biosciences to $75.00 and gave the company a buy rating in a research report on Thursday, March 8th. Finally, Chardan Capital cut Assembly Biosciences from a buy rating to a neutral rating and increased their target price for the company from $35.00 to $50.00 in a research report on Friday, April 13th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Assembly Biosciences has a consensus rating of Hold and an average target price of $60.50.
Shares of Assembly Biosciences opened at $40.61 on Tuesday, according to MarketBeat Ratings. The firm has a market cap of $862.72 million, a price-to-earnings ratio of -16.85 and a beta of 0.79. Assembly Biosciences has a 12-month low of $39.83 and a 12-month high of $40.81.
Assembly Biosciences (NASDAQ:ASMB) last announced its earnings results on Monday, May 7th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $3.57 million for the quarter, compared to the consensus estimate of $1.88 million. Assembly Biosciences had a negative net margin of 379.22% and a negative return on equity of 56.56%. equities research analysts forecast that Assembly Biosciences will post -3.41 earnings per share for the current fiscal year.
In other news, Director William R. Ringo sold 1,000 shares of the stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $49.32, for a total transaction of $49,320.00. Following the completion of the sale, the director now owns 20,465 shares in the company, valued at approximately $1,009,333.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have sold 3,000 shares of company stock valued at $148,750. Company insiders own 18.20% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of ASMB. Jennison Associates LLC lifted its holdings in shares of Assembly Biosciences by 19.6% during the 4th quarter. Jennison Associates LLC now owns 2,120,300 shares of the biopharmaceutical company’s stock valued at $95,944,000 after purchasing an additional 347,025 shares during the last quarter. Farallon Capital Management LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $11,313,000. Emerald Advisers Inc. PA purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $8,673,000. BlackRock Inc. lifted its holdings in shares of Assembly Biosciences by 19.6% during the 4th quarter. BlackRock Inc. now owns 1,078,097 shares of the biopharmaceutical company’s stock valued at $48,784,000 after purchasing an additional 176,976 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in shares of Assembly Biosciences during the 4th quarter valued at $5,068,000. Hedge funds and other institutional investors own 77.28% of the company’s stock.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.